There are now many options to treated relapsed/refractory multiple myeloma (MM); however, these drugs can be costly, and access differs…
Browsing: Acute Lymphoblastic Leukemia
As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease.…
There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows,…
The treatment of relapsed/refractory lymphoma can prove to be challenging. PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) is an oral combination…
An exciting array of data for myeloproliferative neoplasms (MPNs) was presented at the 2018 British Society for Hematology (BSH) Annual…
An upcoming study is investigating a new therapeutic strategy for the treatment of myeloproliferative neoplasms (MPNs). In this interview, Claire…
This is an exciting time for chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs), with new treatments on the horizon.…
Consent for transplant, from both the patient and healthcare professionals, is critical. In this interview, Angela Leather from the Christie…
Post-transplant complications are an important issue to consider and must be managed appropriately. Here, Angela Leather from the Christie NHS…
CAR T-cell agents, as a breakthrough therapy, have their challenges. Here, Rose Ellard from Kings College Hospital NHS Foundation Trust,…
CAR T-cell therapy is a new and exciting advancement for the treatment of hematological cancers. In this interview, Rose Ellard…
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (<1%) tumor PD-L1 on the KEYNOTE-189…
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189…
Amer M Zeidan, MBBS, Gemtuzumab ozogamicin, Antibody Drug Conjugate Broad approval covering front-line & relapse settings at Imedex Great Debates…
Matthew S. Davids, MD, MMSc, Data Combining Venetoclax with Rituximab Half of patients achieved complete remission at Imedex Great Debates…
Richard R. Furman, MD, explains 17P Deleted with TP53 need to be treated differently at Imedex Great Debates 2018.
Jose F. Leis, MD, PhD, explains Chimeric Receptor Therapies for CLL Complete remission rates range from 25-50 at Imedex Great…
Richard M. Stone, MD, explains Use a PCR-based Approach for NMP1 Gene Next-gen sequencing to measure MRD at Imedex Great…
Amer M Zeidan, MBBS, CPX-351, a lysosomal formulation of 7+3 Drug has been tested with significant survival at Imedex Great…
Amer M Zeidan, MBBS, explains Midostaurin – FLT3 Inhibitor Improved survival when drug is added to standard at Imedex Great…
Matthew S. Davids, MD, MMSc, discusses Durability of Response for Agents is Short for Del17P Develop novel combination therapies
Richard R. Furman, MD, PFS has to be Emphasized for CLL Treatments Chemotherapy is unnecessary with novel combinations at Imedex…
Jose F. Leis, MD, PhD, discusses the Sequencing of Therapeutic Interventions Venetoclax outperforms chemoimmunotherapy at Imedex Great Debates 2018.
Richard M. Stone, MD, discusses 4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to…
Amer M Zeidan, MBBS, discusses Novel Treatments for Acute Myeloid Leukemia Four New Drugs Approved at Imedex Great Debates 2018.
Alison Fielding, MD, presents A Patient View at the International Kidney Cancer Symposium 2018
Lisa M Pickering, MD, presents Centralisation of RCC Management: What is the volume needed to improve? The Oncologists View: Is…
Mr. Rajesh Nair FRCS (Urol.), FEBU, MSc., presents Centralisation of Renal Cell Carcinoma Management: What is the Volume Needed to…
Guillermo de Velasco MD, PhD, presents Treatment after Immune checkpoint inhibition: Impact on biology? at the International Kidney Cancer Symposium…
Laurence Albiges, MD, PhD, presents Treatment after immune checkpoint in first/second line setting: Clinical perspective at the International Kidney Cancer…
Ravi Barod PhD FRCS (Urol) presents Minimally invasive partial nephrectomy is NOT a cause of seeding of RCC at the…
Christopher G. Wood, M.D., F.A.C.S. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center,…
Paul Russo, MD, FACS, presents DEBATE: Cancer Seeding and Minimally Invasive Kidney Tumor Surgery at the International Kidney Cancer Symposium…
Co-chair Dr. John P. Leonard summarizing the key take-home points presented during the Lymphoma session at this years Great Debates…
Co-chair Dr. David P. Steensma summarizes the key take-home points presented during the sessions on leukemia, benign hematology, and myeloid…
Guest faculty Dr. Paul G. Richardson summarizes the key take-home points from the presentations comprising this years Plasma Cell Disorders…
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial,…
Sumanta Kumar Pal, M.D. Associate Professor, Department of Medical Oncology & Therapeutics Research Co-Director, Kidney Cancer Program City of Hope…
Bernard Escudier, Gustave Roussy, Villejuif, France asks teh question “Combination Trials with New IO Agents: How Can we Define the…
On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Brian I. Rini, MD, Cleveland Clinic discusses VEGF + I/O combinations in Renal Cell Carcinoma at the 13th European International…
Hans Hammers, MD, PhD, Associate Professor, UT Southwestern takes the pro stance during a debate on IO/IO in 1st Line…
Samra Turajlic, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust CRUK Clinician Scientist, The Francis Crick Institute discusses Tracking…
Dr. Lisa Derosa, MD, PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The Role of the Microbiome in Immunotherapy at…
Samra Turajlic, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust CRUK Clinician Scientist, The Francis Crick Institute discusses the…
Dr James Larkin, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust discusses “Immunotherapy: Bridging Knowledge from Melanoma” from…
Alain Ravaud MD, PhD, of Centre Hospitalier Universitaire de Bordeaux, Bordeaux CHU Bordeaux accepts the P.H.M. DeMulder Memorial Lecture with…
Tim Eisen, University of Cambridge discusses Patient Expectations of Adjuvant Therapy in Kidney Cancer at the 13th European International Kidney…